About
Trastuzumab is a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein. Overexpression of HER2 is observed in a significant proportion of breast and gastric cancers and is strongly associated with aggressive disease and a poorer prognosis. By binding to HER2, trastuzumab effectively inhibits the proliferation of tumor cells that overexpress HER2. Furthermore, it mediates antibody-dependent cell-mediated cytotoxicity (ADCC), where immune cells are recruited to destroy HER2-positive cancer cells, and prevents HER2 cleavage, thereby blocking crucial downstream signaling pathways involved in cell growth and survival. It is a cornerstone therapy for HER2-positive malignancies, frequently used in combination with chemotherapy in both adjuvant (post-surgery) and metastatic settings, or as monotherapy, significantly improving patient outcomes and overall survival rates by targeting the underlying molecular driver of the cancer.
Uses
- Adjuvant treatment of HER2-positive early breast cancer.
- Metastatic HER2-positive breast cancer.
- HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
- Used in patients whose tumors overexpress HER2.
Directions For Use
Administered intravenously by a healthcare professional. The dosage and frequency depend on the specific indication and patient's weight.
Benefits
- Specifically targets HER2-positive cancer cells.
- Significantly improves survival rates in HER2-positive breast cancer.
- Effective in both early and metastatic settings.
- Can be combined with various chemotherapy regimens.
- Reduces the risk of cancer recurrence.
- Well-established efficacy and safety profile.
Side Effects
- Infusion-related reactions
- Fever
- Chills
- Nausea
- Diarrhea
- Headache
- Weakness
- Cardiotoxicity (e.g., heart failure)
- Neutropenia
- Anemia
- Rash
- Cough
Safety Measures
- Alcohol - No specific interaction with alcohol is known; however, general health recommendations apply during cancer treatment.
- Pregnancy - Trastuzumab can cause oligohydramnios and fetal renal dysfunction. It is contraindicated in pregnancy, and effective contraception is required.
- Breastfeeding - It is unknown if trastuzumab is excreted in human milk. Due to potential serious adverse reactions in breastfed infants, breastfeeding is not recommended.
- Liver - Use with caution in patients with severe hepatic impairment; however, no specific dose adjustments are generally required based on liver function alone.
- Kidney - No specific dose adjustments are typically required for renal impairment, but caution is advised, and monitoring may be considered.
- Lung - Pulmonary toxicity, including interstitial pneumonitis, has been reported. Monitor patients for signs of lung disease, especially with concomitant therapies.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!